Liquidia shares plunged nearly 50% after a US court ruled against the company in a patent dispute with United Therapeutics, raising concerns over Yutrepia’s commercial prospects.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.